Histogenics
-
Malvern’s Ocugen Finalizes Reverse Merger, Begins ‘New Chapter’ as a Publicly Traded Company
Ocugen, a gene therapy and biopharmaceutical company in Malvern, has finalized its reverse merger with Histogenics, a publicly traded company in Boston, and is now…
-
Malvern-Based Ocugen Enters Merger Agreement with Company in Boston
Malvern-based Ocugen, a gene therapy and biopharmaceutical company that develops new treatments for rare and underserved eye diseases, has entered into a merger agreement with…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
